Invivyd (IVVD) Preferred Stock Liabilities (2020 - 2021)
Invivyd (IVVD) posted Preferred Stock Liabilities of $504.7 million for Q2 2021, up 197.68% on a QoQ basis from $169.5 million in Q4 2020.
Invivyd (IVVD) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Invivyd's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $504.7 million for Q2 2021.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $504.7 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $504.7 million (changed N/A YoY) and the FY2020 annual result came in at $169.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $504.7 million for Q2 2021 at Invivyd, up from $169.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $504.7 million in Q2 2021 and bottomed at $169.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 504.71 Mn |
| Dec 31, 2020 | 169.55 Mn |